## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.2% in mid entry zone (3.0-6.0%), top quartile (84th pct) cross-sectional ranking. Short-term MRS_5 (3.1%) confirms momentum alignment. Strong momentum (+4.8% 5-day acceleration). Outperforming sector by 3.5%. Caution: overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($354.16)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Top Superinvestors Are Buying Elevance Health (ELV)**
- Source: The Acquirer's Multiple | 20260105T224251 | Bullish | Relevance: 100%
- Several prominent investors, including Glenn Greenberg, Seth Klarman, Jeremy Grantham, and Cliff Asness, significantly increased their holdings in Elevance Health Inc. (ELV) this quarter. This broad-based accumulation signals strong confidence in the company's defensive characteristics, long-term earnings durability, and status as a high-quality healthcare compounder. The buying activity spans value, quantitative, and fundamental investors, reinforcing ELV's appeal across diverse investment strategies.

**2. Elevance Healthâ€™s Stock Holds Its Ground: Defensive Strength In A Market Searching For Direction**
- Source: AD HOC NEWS | 20260105T201816 | Bullish | Relevance: 100%
- Elevance Health's stock has shown consistent growth due to resilient earnings and disciplined capital returns, attracting a "Buy" consensus from Wall Street. Despite market fluctuations, the company's shares reflect a steady, almost stubborn resilience, making it a conviction pick for investors seeking earnings visibility and defensive cash flows. Its strategic shift into value-based care and services, alongside a strong standing in managed care, positions it well for future growth amidst regulatory scrutiny.

**3. Stanley Laman Group Ltd. Cuts Stake in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260106T112011 | Somewhat-Bullish | Relevance: 100%
- Stanley Laman Group Ltd. significantly reduced its stake in Elevance Health, Inc. by 92% in Q3 2025, selling 7,636 shares and ending with 666 shares valued at $215,000. Despite this, major institutional investors like Norges Bank and Vanguard Group continue to hold substantial positions, contributing to an overall institutional ownership of 89.24%. Elevance Health exceeded Q3 expectations with an EPS of $6.03 and 12% revenue growth, offering an annualized dividend of $6.84, yielding approximately 1.9%.

**4. Wellpoint Data Breach Exposes Protected Health Information (PHI)**
- Source: Claim Depot | 20260105T172804 | Somewhat-Bearish | Relevance: 100%
- Wellpoint, a health insurance provider affiliated with Elevance Health, reported a data breach to the U.S. Department of Health and Human Services on October 7, 2025. The incident involved unauthorized access to sensitive personally identifiable information (PII) and protected health information (PHI), potentially including names, Social Security numbers, medical records, and insurance details. Wellpoint has launched an investigation, secured its systems, and notified affected individuals, advising them to monitor their credit and insurance statements.

**5. LS Investment Advisors LLC Buys New Shares in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260105T133212 | Bullish | Relevance: 100%
- LS Investment Advisors LLC has acquired a new stake of 3,150 shares in Elevance Health, Inc. (NYSE:ELV) during the third quarter, valued at approximately $1,018,000. Elevance Health exceeded Q3 earnings expectations and saw significant increases in institutional ownership from major firms such as Norges Bank, Sanders Capital, Vanguard, and The Manufacturers Life Insurance Company. Currently, institutional investors and hedge funds own 89.24% of the stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $404 | $385 | +5% |
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Overweight |
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $83.6B |
| Beta | 0.52 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 13.8 |
| Current P/E | 12.4 |
| YoY Growth | -10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.3% to 5.2% (+4.8% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 84th percentile. MRS_5 at 3.1% confirms short-term momentum alignment. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.72), confirming momentum. RSI overbought at 72, risk of mean reversion. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.18% (CS: 84) | Strong |
| RSI_14 | 72.0 | Overbought |
| MACD Histogram | 1.72 | Bullish |
| vs SMA20 | 1.064x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $371.54
- **Stop Loss:** $354.16 (4.7% risk)
- **Target:** $397.61 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 75
- **Position Value:** $27,865.50
- **Portfolio %:** 27.87%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*